Endovastec™ Minos™ Receives Approval for Marketing in Colombia

Bogota, Colombia, 24 August 2022 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently received registration approval from the Colombian National Institute for Drug and Food Surveillance (INVIMA) for the Minos™ Abdominal Aortic Stent-Graft and Delivery System (“Minos™ System”). Colombia becomes the third Latin American country to approve the Minos™ System, after Brazil and Argentina. The Minos™ System obtained CE marking in 2019 and has been available in 12 overseas markets including Greece, Poland, Spain, Germany, Italy, Croatia, Hungary, Switzerland, Brazil, the Czech Republic, and the United Kingdom.

As a brand new abdominal aortic stent-graft system independently developed by Endovastec™, the Minos™ System is designed for the interventional therapy of infrarenal aortic aneurysms. It is the first domestically made stent-graft system which features an ultra-low profile delivery system with an outer diameter of 14F. This breakthrough technology significantly reduces the vessel access required for the endovascular aneurysm repair of abdominal aortic aneurysms. The Minos™ System features a three-piece design, which enables flexible assembly to accommodate different size requirements, and offers distinct benefits in the treatment of complex abdominal aortic aneurysm conditions, such as tortuous or short aneurysm neck, distorted and narrow access, etc. Since its launch, the Minos™ System has earned widespread acceptance from senior experts in the field of endovascular aortic repair (EVAR) at home and abroad, thanks to its consistent clinical performance and excellent treatment results.

Colombia, the third most populous country in Latin America, relies heavily on imports of medical devices. The country’s market size has grown rapidly in recent years, with a high demand for aortic and peripheral vascular intervention products. The approval of the Minos™ System in Colombia, following the Endovastec™ Hercules™ line of products, is expected to build a solid foundation for the Company’s development in the Latin American market and expedite the global presence of its products. In the future, Endovastec™ will continue to introduce more high-quality and innovative medical devices to Colombia to benefit more patients in the country.

About Endovastec™

Founded in Shanghai in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™", stock code: 688016.SH), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is a global medical device company focusing on R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices. Its product portfolio includes thoracic and abdominal aortic stent grafts, intraoperative stents, drug-coated PTA balloon catheters, and PTA balloon catheters. At Endovastec™, we are breaking barriers and accelerating access to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping life, and to build a people-centric enterprise as a global leader of evolving and emerging medical technologies through continuous innovation.

More information is available at www.endovastec.com.